Novartis’ canakinumab cuts risk for heart attack survivors
Novartis to discuss canakinumab results with regulators.
X
Novartis’ canakinumab cuts risk for heart attack survivors
https://pharmaphorum.com/news/novartis-canakinumab-reduces/
heart failure
Blow for Novartis as heart failure drug flops
Could this be the end of the road for serelaxin?
MSD and Bayer launch big gamble on heart failure candidate
Aims to recruit 4,900 patients to prove value in heart failure
Medtronic to buy HeartWare, expand heart failure portfolio
Deal worth an estimated $1.1 billion.
